Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice

Cancer

Volumn 94, Issue 2, 2002, Pages 406-414

  Gotsman, Israel ^a   Alper, Ruslana ^a   Klein, Athalia ^a   Rabbani, Elazar ^b   Engelhardt, Dean ^b   Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Enzon Incorporated   (United States)

Author keywords

Hepatocellular carcinoma; Immune response; Splenocytes; Tumorassociated antigens

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; TUMOR ANTIGEN; VIRUS ENVELOPE PROTEIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNOREGULATION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR VOLUME;

ADMINISTRATION, ORAL; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; BODY WEIGHT; CARCINOMA, HEPATOCELLULAR; CYTOKINES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNE TOLERANCE; INTERFERON TYPE II; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTES;

EID: 0037080116     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10237     Document Type: Article

References (55)

1. Prognosis of primary hepatocellular carcinoma
2. Treatment of small hepatocellular carcinomas
3. Hepatocellular carcinoma and the hepatitis B virus: Evidence for a casual association
4. Hepatitis B virus immunopathogenesis
5. Viruses, immunity and cancer: Lessons from hepatitis B
6. Intrahepatic T cells in hepatitis B: Viral controls versus liver cell injury
7. Cytokines in viral hepatitis
8. Induction of oral tolerance towards hepatitis B virus: Can we eat the disease and live with the virus?
9. Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen
10. Oral tolerance
11. Vaccination by inducing oral tolerance
12. Induction of autoimmune diabetes by oral administration of autoantigen
13. Immune response to dietary antigens: Oral tolerance
14. Oral tolerization to adenoviral antigens permits long term gene expression using recombinant adenoviral vectors
15. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenovirus
16. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model
17. Oral tolerization to hepatitis B virus proteins ameliorates hepatic inflammation in Tupia carrying hepatitis B viral infection
18. Oral immune regulation towards hepatitis B virus proteins - A new mode of treatment for chronic HBV infection: Results of a Phase I clinical trial
19. Comparative morphology and tumorigenicity of human hepatocellular cell carcinoma lines in athymic rats and mice
20. Improved immunogenicity in mice of mammalian cell derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens, compared to conventional yeast derived vaccines
21. Adoptive transfer of immunity to hepatitis B virus in mice following bone marrow transplantation through immunization of bone marrow donors
22. Improved double antibody radioimmunoassay (RIA-DA) methodology for detecting hepatitis B antigen and antibody
23. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans
24. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
25. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection
26. Ablation of persistent hepatitis B by allogeneic bone marrow transplantation from an HBV immune donor
27. Adoptive transfer of immunity to hepatitis B in humans following T-depleted bone marrow transplantation from HBV immune donors
28. Natural killer cells and tumor therapy
29. Infection, immunity, and cancer
30. Tumor immunotherapy: Developments and strategies
31. Persistent infection of humans with hepatitis B virus: Mechanisms and consequences
32. The role of virus specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection
33. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection
34. The hepatitis B virus specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection
35. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a non-cytolytic mechanism in transgenic mice
36. Viral clearance without destruction of infected cell during acute HBV infection
37. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic nice
38. Cytokine-mediated control of viral infections
39. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity
40. A peptide derived from an autoantibody can stimulate T cells in the (NZB × NZW) F1 mouse model of systemic lupus erythematosus
41. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
42. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice
43. Treatment of experimental colitis by oral tolerance induction: A central role for suppressor lymphocytes
44. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice
45. Induction of oral tolerance in splenocyte recipients towards pre-transplant antigens ameliorates chronic graft versus host disease in a murine model
46. Liver associated lymphocytes expressing NK1.1 are essential for oral tolerance induction in a murine model
47. Double-blind pilot trial of oral tolerization with myelin antigen in multiple sclerosis
48. Effects of oral administration of type II collagen on rheumatoid arthritis
49. Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis
50. Adenovirus-mediated gene therapy of liver diseases
51. Induction of tolerance to recombinant adenoviruses by injection into newborn rats: Long term amelioration of hyperbilirubinemia in Gunn rats
52. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long term gene therapy in Gunn rats
53. Transient immunosuppression with FK506 permits long term expression of therapeutic genes introduced into the liver using recombinant adenoviruses
54. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long term gene expression
55. Adoptive transfer of tolerance from rats tolerized to adenoviral antigens allows long term adenovirus-mediated gene therapy in Gunn rats